Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406656 | 1.00 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL406657 | 1.00 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL10246744 | 0.88 | SLC7A5 (0.42) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL3420016 | 0.85 | L3MBTL1 (0.50) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL13146420 | 0.83 | KDM1A (0.42) | L3MBTL1TDP1RAB9AKDM1AALDH1A1 | |
| SCHEMBL9968919 | 0.81 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL13145859 | 0.81 | SLC7A5 (0.42) | SLC7A5L3MBTL1TDP1RAB9ALOXL2 | |
| SCHEMBL407531 | 0.80 | SLC7A5 (0.39) | SLC7A5L3MBTL1TDP1RAB9ASMN1; SMN2 | |
| SCHEMBL407530 | 0.80 | SLC7A5 (0.39) | SLC7A5L3MBTL1TDP1RAB9ASMN1; SMN2 | |
| SCHEMBL9968916 | 0.80 | SLC7A5 (0.39) | SLC7A5L3MBTL1TDP1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SLC7A5 2990/4885L3MBTL1 4637/4885TDP1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.